Simona Roggero, PhD | Fidelio Medical srl; Fabiana Arduini, PhD
Competition Sponsor: EIT Health of the European Union
Awardee Year: 2022
Fidelio Medical is developing the first comprehensive screening program for iron disorders, to facilitate access to screening, monitoring and consulting experts for iron disorders. 1 in 3 people suffer from iron disorders, in particular women, people with chronic illnesses and the elderly. If left untreated iron diseases can lead to serious problems, from anemia to chronic mental and physical fatigue, disability, heart and kidney disease. Blood iron is affected by diet and abnormally high or low levels are linked to age-related conditions such as Parkinson’s disease, liver disease and a decline in the body’s ability to fight infection in older age. Blood iron levels could be key to slowing ageing.
Early detection of iron deficiency or overload is critical for targeted, preventative treatment. Also, monitoring iron levels using our simpler tool will increase understanding of the role of iron in aging.
Fidelio Medical’s innovative electrochemical sensors have been combined to provide reliable, easy-to-use digital diagnostics out of the lab.
We will allow iron metabolism multi-marker screening out of the lab, at home and during medical visits, in screening program. Through our algorithm we will correlate them supporting clinical decisions and also researchs in this specific area.
Existing point-of-care solutions can only detect either ferritin, that alone leads to misdiagnosis in more than 50% of cases, or hemoglobin, which alone signals anemia, an already advanced state of iron deficiency.
Fidelio diagnostic units, based on multi-marker analysis in the Fe2+ and Fe3+ zone, will provide comprehensive and frequent monitoring of the iron panel settings.
Fidelio is also developing a digital platform around its point-of-care diagnostic unit. The platform collects, elaborates and reports data from point-of-care testing. In Fidelio Medical’s digital space, patients access iron disorders risk assessments and on-demand services, and physicians provide evidence-based support, enabling continuous monitoring and preemptive treatment.
The integration of the diagnostic units with a digital platform will allow data collection, data development through algorithms and new high-quality digital consulting services.
We are collaborating with key international experts in the iron disorders field.
Our data into the hand of our strong experts network will support the main research projects worlwide involved in the area of better understanding of the blood iron involvement in the slow ageing.
Fidelio Medical is developing the first comprehensive screening program for iron disorders, to facilitate access to screening, monitoring and consulting experts for iron disorders. 1 in 3 people suffer from iron disorders, in particular women, people with chronic illnesses and the elderly. If left untreated iron diseases can lead to serious problems, from anemia to chronic mental and physical fatigue, disability, heart and kidney disease. Blood iron is affected by diet and abnormally high or low levels are linked to age-related conditions such as Parkinson’s disease, liver disease and a decline in the body’s ability to fight infection in older age. Blood iron levels could be key to slowing ageing.
Early detection of iron deficiency or overload is critical for targeted, preventative treatment. Also, monitoring iron levels using our simpler tool will increase understanding of the role of iron in aging.
Fidelio Medical’s innovative electrochemical sensors have been combined to provide reliable, easy-to-use digital diagnostics out of the lab.
We will allow iron metabolism multi-marker screening out of the lab, at home and during medical visits, in screening program. Using our algorithm, we will correlate them in support of clinical decisions and research in this particular area.
Existing point-of-care solutions can only detect either ferritin, that alone leads to misdiagnosis in more than 50% of cases, or hemoglobin, which alone signals anemia, an already advanced state of iron deficiency.
Fidelio diagnostic units, based on multi-marker analysis in the Fe2+ and Fe3+ zone, will provide comprehensive and frequent monitoring of the iron panel settings.
Fidelio is also developing a digital platform around its point-of-care diagnostic unit. The platform collects, elaborates and reports data from point-of-care testing. In Fidelio Medical’s digital space, patients access iron disorders risk assessments and on-demand services, and physicians provide evidence-based support, enabling continuous monitoring and preemptive treatment.
The integration of the diagnostic units with a digital platform will allow data collection, data development through algorithms and new high-quality digital consulting services.
We are collaborating with key international experts in the iron disorders field.
Our data into the hand of our strong experts network will support the main research projects worlwide involved in the area of better understanding of the blood iron involvement in the slow ageing.
To learn more about this proposal, email healthylongevity@nas.edu.